Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
A physician outlines the RAND Health Insurance Experiment and its conclusion that the deductible feature of consumer-directed health plans can reduce health care spending significantly.